Pharmacology Watch – July 1, 2016
July 1, 2016
View Archives Issues
-
Research: Using Generic Drugs Could Lead to Billions in Savings
If therapeutic substitution of a generic within the same class had been used instead of the branded equivalent, $73 billion could have been saved, including nearly $25 billion in out-of-pocket expenditures for patients.
-
FDA Actions
In this section: FDA approves a subdermal buprenorphine implant for maintenance treatment of opioid dependence; warns health professionals against using ketoconazole for the treatment of skin and nail fungal infection; investigates a possible link between canagliflozin and an increase in leg and foot amputations; advises against using fluoroquinolones for common infections; and green lights daclizumab for the treatment of relapsing multiple sclerosis.